833 related articles for article (PubMed ID: 33059228)
1. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
2. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
5. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
7. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
9. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
11. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
McCann KE
Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
[TBL] [Abstract][Full Text] [Related]
12. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
13. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
14. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
16. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
[TBL] [Abstract][Full Text] [Related]
17. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
18. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
19. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
20. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]